Media February 23, 2023: Les Echos Investir – Maat Pharma : l’approche novatrice du microbiote (French only) https://investir.lesechos.fr/conseils-boursiers/conseils-actions/maat-pharma-lapproche-novatrice-du-microbiote-1909546MaaT PharmaMarch 13, 2023
Media February 22, 2023: Microbiome Post – Interview of Hervé Affagard During the 8th Microbiome Movement – Drug Development Summit, held in London at the end…MaaT PharmaMarch 8, 2023
Media December 13, 2022: BSmart interview of Hervé Affagard – Smart Tech (French only) (French only)MaaT PharmaDecember 13, 2022
Media December 13, 2022: BFM Business interview of Hervé Affagard – Good Morning Business (French only)MaaT PharmaDecember 13, 2022
Media MedNous – FDA approves first faecal microbiota product Hervé Affagard, CEO and co-founder of MaaT Pharma, commented on the first FDA-approval for a…MaaT PharmaDecember 2, 2022
Media Labiotech – FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field Hervé Affagard, CEO and co-founder of MaaT Pharma, commented on the first FDA-approval for a…MaaT PharmaDecember 2, 2022
Media Labiotech – MaaT Pharma: leading the charge in microbiome therapeutics MaaT PharmaNovember 15, 2022
Media October 13, 2022: Replay of Microbiome session of the 2022 edition of HTID with Hervé Affagard 2022 edition of HealthTech Innovation Days: replay of "Translational microbiome medicine to treat serious oncology…MaaT PharmaOctober 21, 2022
Media October 12, 2022: Interview of Hervé Affagard in Lyon Décideurs – Bourses & Valeurs Interview of Hervé Affagard, CEO and co-founder of MaaT Pharma, for Lyon Décideurs - Bourses…MaaT PharmaOctober 18, 2022
Media October 10, 2022: Interview of Hervé Affagard in La Bourse et la Vie La Bourse et la Vie interviewed Hervé Affagard, CEO and co-founder of MaaT Pharma, during…MaaT PharmaOctober 13, 2022